Trending...
- UK Financial Ltd Makes History as MayaCat (SMCAT) Becomes the World's First Exchange-Traded ERC-3643 Security Token
- High-Impact Mental Health Platform Approaching a Defining Regulatory Moment: Eclipsing 70,000 Patients on Real World Use of Ketamine: N ASDAQ: NRXP
- $26 Billion Global Market by 2035 for Digital Assets Opens Major Potential for Currency Tech Company with ATM Expansion and Deployment Plans Underway
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL) a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced that the Company will participate in the H.C. Wainwright Cell Therapy Virtual Conference taking place February 28, 2023.
Details for the virtual fireside chat are as follows:
Date: Tuesday, February 28, 2023
Time: 2:00 PM ET
The fireside chat will be available via a live webcast accessible on Precision's website in the Investors section under Events & Presentations on February 28, 2023: https://investor.precisionbiosciences.com/events-and-presentations. An archived replay will be available for approximately 30 days following the event.
More on ncarol.com
About Precision BioSciences, Inc.
Precision BioSciences, Inc. is a clinical stage biotechnology company dedicated to improving life (DTIL) with its novel and proprietary ARCUS® genome editing platform. ARCUS is a highly precise and versatile genome editing platform that was designed with therapeutic safety, delivery, and control in mind. Using ARCUS, the Company's pipeline consists of multiple ex vivo "off-the-shelf" CAR T immunotherapy clinical candidates and several in vivo gene editing candidates designed to cure genetic and infectious diseases where no adequate treatments exist. For more information about Precision BioSciences, please visit www.precisionbiosciences.com.
Contacts
Investor Contact:
Mei Burris
Director, Investor Relations & Finance
Mei.burris@precisionbiosciences.com
Media Contact:
Maurissa Messier
Senior Director, Corporate Communications
Maurissa.Messier@precisionbiosciences.com
Details for the virtual fireside chat are as follows:
Date: Tuesday, February 28, 2023
Time: 2:00 PM ET
The fireside chat will be available via a live webcast accessible on Precision's website in the Investors section under Events & Presentations on February 28, 2023: https://investor.precisionbiosciences.com/events-and-presentations. An archived replay will be available for approximately 30 days following the event.
More on ncarol.com
- A High-Velocity Growth Story Emerges in Marine and Luxury Markets
- $26 Billion Global Market by 2035 for Digital Assets Opens Major Potential for Currency Tech Company with ATM Expansion and Deployment Plans Underway
- 1300+ Small Business Leaders Sign Letter to Congress Urging Prompt Action to Protect US Innovation
- Peernovation 365 is Now Available
- Snap-a-Box Brings Texas' First Robot-Cooked Chinese Takeout to Katy–Fulshear
About Precision BioSciences, Inc.
Precision BioSciences, Inc. is a clinical stage biotechnology company dedicated to improving life (DTIL) with its novel and proprietary ARCUS® genome editing platform. ARCUS is a highly precise and versatile genome editing platform that was designed with therapeutic safety, delivery, and control in mind. Using ARCUS, the Company's pipeline consists of multiple ex vivo "off-the-shelf" CAR T immunotherapy clinical candidates and several in vivo gene editing candidates designed to cure genetic and infectious diseases where no adequate treatments exist. For more information about Precision BioSciences, please visit www.precisionbiosciences.com.
Contacts
Investor Contact:
Mei Burris
Director, Investor Relations & Finance
Mei.burris@precisionbiosciences.com
Media Contact:
Maurissa Messier
Senior Director, Corporate Communications
Maurissa.Messier@precisionbiosciences.com
Filed Under: Business
0 Comments
Latest on ncarol.com
- High-End Exterior House Painting in Boulder, Colorado
- Simpson and Reed Co-Founders Shardé Simpson, Esq. and Ciara Reed, Esq. Launch "Hello Wilma,"
- Report Outlines Key Questions for Individuals Exploring Anxiety Treatment Options in Toronto
- Rande Vick Introduces Radical Value, Challenging How Brands Measure Long-Term Value
- Lisa Mauretti Launches Peace of Mind Travel Coaching to Guide Fearful Travelers to Discover the World with Confidence
- New Year, New Home: Begin 2026 at Heritage at South Brunswick
- Food Journal Magazine Releases Its 'Best Food In Los Angeles Dining' Editorial Section
- Enders Capital: 25% Gains with Just -0.80% Maximum Monthly Drawdown in Volatile Debut Year 2025
- CES Spotlight Highlights Need for Strategic Review as Throughput Demands Evolve
- ASR Media, Social T Marketing & PR Announce Merger
- $780,000 Project for New Middle East Police Service with Deposit Received and Preliminary Design Work Underway for Lamperd: Stock Symbol: LLLI
- The 3rd Annual Newark Summit for Real Estate, Economic Development & Placemaking Returns February 9th
- Wespor Business Launches Shared Direct Mail Program at $0.06 per Household
- Ski Safety Awareness Month highlights why seeing clearly and wearing modern protection matters more than ever
- Vent Pros Expands Operations into Arizona to Meet Growing Demand for Commercial Ventilation and Kitchen Hood Cleaning Services
- Kindred Spirits: A Devotional for Those Loving Someone Through Addiction
- Klein Civil Rights Expands with New Offices in New York's Historic Woolworth Building
- Biz Hub Financial Hosts 9th Annual Client Appreciation Event, Awards $1,000 CARES Community Grant
- Green Office Partner Appoints Aaron Smith as Chief Revenue and Growth Officer
- A Family Completes a Full Circumnavigation of the Globe in a Self-Contained Camper Van